← Back to Patent Explorer
US4434159A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom

Assignee: Teijin Ltd
•
Filing: 1981-03-31
•
Granted: 1984-02-28
•
Expires: 2001-03-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A pharmaceutical composition for intrarectal administration comprising a pharmaceutically effective amount of an active ingredient which when administered alone to the rectum, is substantially unabsorbable into the living body through the mucous membrane of the rectum, said composition further containing an absorption aid acting within the rectum in such a way as to induce absorption of said active ingredient through the rectal mucous membrane, said absorption aid being characterized by (1) being substantially nontoxic to living organisms, (2) containing in the molecule at least two hydrophilic groups selected from the class consisting of carboxyl groups, acidic hydroxyl groups, carboxyl groups in the form of pharmaceutically acceptable salts, acidic hydroxyl groups in the form of pharmaceutically acceptable salts, carboxyl groups in the form of amides and acidic hydroxyl groups in the form of esters, (3) containing in the molecule at least two lipophilic groups selected from the class consisting of groups of the formulae ##STR1## and -CH 2 -, the number of the lipophilic groups being not less than that of the hydrophilic groups, and (4) having a molecular weight of from about 100 to about 300; and a suppository prepared therefrom in unit dosage form.

Inventors

  • 👤 Kunio Sekine
  • 👤 Yoshiki Suzuki
  • 👤 Gentaro Yamashita
  • 👤 Hisao Yamaguchi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 16:02
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/06; A61K47/16; A61K47/18; A61K47/183; A61K47/08; A61K47/12; A61K47/22; A61K9/00; A61K9/02; Y; Y10; Y10S; Y10S424/00; Y10S424/15

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 149 words
A pharmaceutical composition for intrarectal administration comprising a pharmaceutically effective amount of an active ingredient selected from the group consisting of peptide hormones and polysaccharides, which when administered alone to the rectum, is substantially unabsorbable into the living body through the mucous membrane of the rectum, said composition further containing an absorption aid acting within the rectum in such a way as to induce absorption of said active ingredient through the rectal mucous membrane, said absorption aid being characterized by (1) being substantially nontoxic to living organisms, and (2) having a molecular weight of from about 100 to about 300, and being selected from the group consisting of ascorbic acid or a pharmaceutically acceptable salt thereof, salicylic acid, an ester thereof at its acidic hydroxyl group, or a pharmaceutically acceptable salt thereof at the carboxyl group and pyroglutamic acid, or a pharmaceutically acceptable salt thereof at the carboxyl group.
Claim 2
Dependent Claim 149 words
A pharmaceutical composition for intrarectal administration comprising a pharmaceutically effective amount of an active ingredient selected from the group consisting of peptide hormones and polysaccharides, which when administered alone to the rectum, is substantially unabsorbable into the living body through the mucous membrane of the rectum, said composition further containing an absorption aid acting within the rectum in such a way as to induce absorption of said active ingredient through the rectal mucous membrane, said absorption aid being characterized by (1) being substantially nontoxic to living organisms, and (2) having a molecular weight of from about 100 to about 300, and being selected from the group consisting of ascorbic acid or a pharmaceutically acceptable salt thereof, salicylic acid, an ester thereof at its acidic hydroxyl group, or a pharmaceutically acceptable salt thereof at the carboxyl group and pyroglutamic acid, or a pharmaceutically acceptable salt thereof at the carboxyl group.
Claim 3
Dependent Claim 18 words
A composition of claim 1 wherein the absorption aid is ascorbic acid or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim 18 words
A composition of claim 2 wherein the pharmaceutically acceptable salt of ascorbic acid is sodium or potassium ascorbate.
Claim 5
Dependent Claim 30 words
A composition of claim 1 wherein the absorption aid is salicylic acid, an ester thereof at its acidic hydroxyl group, or a pharmaceutically acceptable salt thereof at the carboxyl group.
Claim 6
Dependent Claim 19 words
A composition of claim 4 wherein the ester at the acidic hydroxyl group of salicylic acid is acetylsalicylic acid.
Claim 7
Dependent Claim 26 words
A composition of claim 4 wherein the pharmaceutically acceptable salt at the carboxyl group is a sodium or potassium salt of salicyclic acid or acetylsalicyclic acid.
Claim 8
Dependent Claim 12 words
A composition of claim 1 wherein the absorption aid is pyroglutamic acid.
Claim 9
Dependent Claim 13 words
A composition of claim 1 wherein the active ingredient is a peptide hormone.
Claim 10
Dependent Claim 13 words
A composition of claim 8 wherein the peptide hormone is calcitonin or insulin.
Claim 11
Dependent Claim 12 words
A composition of claim 1 wherein the active ingredient is a polysaccharide.
Claim 12
Dependent Claim 10 words
A composition of claim 10 wherein the polysaccharide is heparin.
Claim 13
Dependent Claim 27 words
A composition of claim 1 wherein the amount of the absorption aid is about 0.1 to 40% by weight based on the weight of the pharmaceutical composition.
Claim 14
Dependent Claim 13 words
A suppository in unit dosage form comprising the pharmaceutical composition of claim 1.
Claim 15
Dependent Claim 16 words
A suppository of claim 13 having a solid base capable of becoming flowable in the rectum.
Claim 16
Dependent Claim 23 words
A suppository of claim 13 having a substance liquid at room temperature as a main base and being coated with a gelatin film.

References Cited (Backward Citations)

GB1462399A Cited
US4164573A Cited
GB1563311A Cited
US4156719A Cited
US4277465A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-02-27 1987-08-29 1988-02-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-02-27 1991-08-29 1992-02-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-02-27 1995-08-29 1996-02-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag